kyron.bio’s aims to address issues in biologic drug development. The company is focused on controlling sugar molecules, known as glycans, on the surface of drugs to address issues such as varying efficacy and the risk of side effects.
kyron.bio has raised €5.5M across 1 funding round from 5 investors, most recently a round in May 2025. Based in Paris, France; active in Healthtech. Data as of 6 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-05-28 | Other | €5.5M |
| Angel Investors,Entrepreneur First,HCVC,Saras Capital,Verve Ventures |
| View deal → |
